Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT ...

Retrieved on: 2021-04-10 12:56:15

Tags for this article:

Clinical medicine

Medicine

Antibody-drug conjugate

Biotechnology

Immunology

Tumor microenvironment

Immunotherapy

Patient derived xenograft

Mersana Therapeutics Inc

Immunosynthen

Click the tags to see associated articles and topics

Mersana Therapeutics Presents Preclinical Data Highlighting Potential of XMT-2056 and XMT .... View article details on HISWAI: https://www.globenewswire.com/news-release/2021/04/10/2207793/0/en/Mersana-Therapeutics-Presents-Preclinical-Data-Highlighting-Potential-of-XMT-2056-and-XMT-1660-in-Three-Posters-at-Virtual-2021-AACR-Annual-Meeting.html

Excerpt

“The ability of Immunosynthen-based ADCs to activate the innate immune system via STING in tumor cells in addition to tumor-resident immune cells ...

Article found on: www.globenewswire.com

View Original Article